Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
ALLO - Allogene Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.43
DETAILS
HIGH:
$9.00
LOW:
$3.85
MEDIAN:
$6.42
CONSENSUS:
$6.43
UPSIDE:
221.50%
Stock News
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics Q1 Earnings Call Highlights
Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April financing.
Allogene Therapeutics ends China cell therapy deal with Overland
Allogene Therapeutics said on Wednesday it has ended a key partnership for developing cell therapies in parts of Asia and reworked its equity stake in partner Overland Therapeutics.
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended March 31, 2026.
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif.
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation treatment for patients with large B-cell lymphoma (LBCL).
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif.
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 13.1% After Analyst Upgrade
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) shares shot up 13.1% during mid-day trading on Thursday after JPMorgan Chase and Co. upgraded the stock from an underweight rating to a neutral rating. The company traded as high as $2.45 and last traded at $2.4550. 4,605,023 shares were traded during trading, a decline of 45%
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. In addition, the underwriters partially exercised their option and purchased 12,700,000 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from this offering were $200.4 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene.
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of pre-clinical data for ALLO-329 in Nature Communications. ALLO-329 is an investigational allogeneic CAR T product developed specifically for autoimmune diseases.
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds from this offering are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions. In addition, Allogene has granted the underwriters for the offering a 30-day option to purchase up to 13,125,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study
Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling potential in first-line LBCL treatment.
Traders Purchase High Volume of Allogene Therapeutics Call Options (NASDAQ:ALLO)
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) was the target of some unusual options trading activity on Monday. Investors acquired 6,076 call options on the stock. This is an increase of approximately 901% compared to the average volume of 607 call options. Allogene Therapeutics Trading Up 11.7% Shares of ALLO stock opened at $3.04
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million of shares of its common stock. All of the shares are being offered by Allogene. In addition, Allogene intends to grant the underwriters for the offering a 30-day option to purchase up to an additional $26.25 million of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript
Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL
Allogene Therapeutics is positioned for a paradigm shift in CAR T therapy with cema-cel, targeting earlier, scalable intervention in high-risk LBCL. ALPHA3 interim data showed 58.3% MRD negativity for cema-cel versus 16.7% for observation, with a notably clean safety profile and outpatient feasibility. ALLO's sub-$500M enterprise value suggests the market is only partially pricing in the platform's potential, despite a sharp post-data rally.
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ: ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (M.
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30% MRD Reduction Occurred Rapidly Following Cema-Cel Treatment with a 97.7% Median Decrease in Plasma ctDNA at Day 45 Compared to a 26.6% Median Increase in the Observation Arm Cema-Cel Treatment Well-Tolerated with Most Patients Managed Outpatient No Cases of CRS, ICANS, GvHD, or Treatment-Related Serious Adverse Events No Hospitalizations for Treatment-Related Adverse Events Community Cancer Centers, Including Sites New to CAR T Therapy, Accounted for Approximately 33% of Screening Activity and Cema-Cel Infusions Enrollment Expected to Complete by Year-End 2027, with an Interim Event-Free Survival (EFS) Analysis Anticipated in Mid-2027 and Primary EFS in Mid-2028 Conference Call and Webcast Scheduled for Today at 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today reported data from the planned interim futility analysis of its pivotal, randomized Phase 2 ALPHA3 trial in first-line (1L) consolidation large B-cell lymphoma (LBCL).
Price Targets
Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein
$3.85
(was $3.06)
Bernstein
Allogene Therapeutics price target raised to $9 from $7 at Baird
$9.00
(was $3.06)
Robert W. Baird
Allogene (ALLO) PT Lowered to $9 at H.C. Wainwright
$9.00
(was $2.98)
Debjit Chattopadhyay
·
H.C. Wainwright
Allogene (ALLO) PT Lowered to $7 at B.Riley
$7.00
(was $2.90)
Kalpit Patel
·
B.Riley Financial
Allogene Therapeutics (ALLO) Stock Price: $11 Target From Baird
$11.00
(was $9.74)
Jack Allen
·
Robert W. Baird
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
$35.00
(was $15.29)
Michael Schmidt
·
Guggenheim
Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord
$55.00
(was $17.62)
John Newman
·
Canaccord Genuity
Allogene (ALLO) PT Lowered to $30 at Jefferies
$30.00
(was $13.13)
Biren Amin
·
Jefferies
Allogene (ALLO) PT Lowered to $32 at BofA Securities
$32.00
(was $13.13)
Jason Gerberry
·
Bank of America Securities
Allogene Therapeutics price target lowered to $40 from $44 at Oppenheimer
$40.00
(was $13.13)
Mark Breidenbach
·
Oppenheimer
Allogene Therapeutics price target lowered to $35 from $60 at Roth Capital
$35.00
(was $13.13)
Anthony Butler
·
Roth Capital
Allogene Therapeutics upgraded to Outperform from Market Perform at Raymond James
$36.00
(was $27.64)
Dane Leone
·
Raymond James